Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2004 Dec;96(12):1587–1593.

Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancer.

Reena B Wyatt 1, Ricardo F Sánchez-Ortiz 1, Christopher G Wood 1, Edilberto Ramirez 1, Christopher Logothetis 1, Curtis A Pettaway 1
PMCID: PMC2568655  PMID: 15622688

Abstract

BACKGROUND: African-American men suffer disproportionately with respect to the incidence and mortality from prostate cancer. The objective of the current study was to define if race was an independent prognostic factor among other variables assessed for survival among men treated for androgen independent prostate cancer. METHODS: Between 1988 and 1995, 379 patients with AIPC and clinical progression were referred for novel protocol therapies. Measured variables included: 1) patient age, 2) race or ethnicity, 3) hemoglobin, 4) alkaline phosphatase, 5) serum prostate-specific antigen (PSA) level, 6) time from hormonal ablation to AIPC, 7) number of metastases on bone scan, 8) osseous stage, 9) number of organ systems with metastases and 10) type of treatment for AIPC. RESULTS: Median survival for the cohort was not significantly affected by race, on uni- or multivariate analysis. Multivariate analysis demonstrated that increasing hemoglobin (HR = 0.87 per g, 95% CI [0.81-0.94]) and time to AIPC (HR = 0.994, 95% CI [0.990-0.998]) were associated with increased survival while higher osseous stage (HR = 1.49, stage I versus II, 95% CI [1.11-1.99]), treatment group (HR = 1.68, treatment group I versus II, 95% CI [1.33-2.12]), metastases to three or more organ systems (HR = 1.31 versus less than three organs, 95% CI [1.15-1.49]), and advanced age (HR = 1.51 for age > 70 versus < or = 70, 95% CI [1.18-1.94]) were associated with a decrease in survival among patients with AIPC. CONCLUSION: Independent prognostic variables for survival among patients with AIPC included patient age, serum hemoglobin level, time to androgen-independent disease, treatment group and the extent of metastatic disease. Ethnicity did not adversely affect outcome.

Full text

PDF
1587

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brawn P. N., Johnson E. H., Kuhl D. L., Riggs M. W., Speights V. O., Johnson C. F., 3rd, Pandya P. P., Lind M. L., Bell N. F. Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer. 1993 Apr 15;71(8):2569–2573. doi: 10.1002/1097-0142(19930415)71:8<2569::aid-cncr2820710822>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  2. Cersosimo R. J., Carr D. Prostate cancer: current and evolving strategies. Am J Health Syst Pharm. 1996 Feb 15;53(4):381–448. doi: 10.1093/ajhp/53.4.381. [DOI] [PubMed] [Google Scholar]
  3. Eisenberger M. A., Crawford E. D., Wolf M., Blumenstein B., McLeod D. G., Benson R., Dorr F. A., Benson M., Spaulding J. T. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol. 1994 Oct;21(5):613–619. [PubMed] [Google Scholar]
  4. Fowler J. E., Bigler S. A., Renfroe D. L., Dabagia M. D. Prostate specific antigen in black and white men after hormonal therapies for prostate cancer. J Urol. 1997 Jul;158(1):150–154. doi: 10.1097/00005392-199707000-00047. [DOI] [PubMed] [Google Scholar]
  5. Fowler J. E., Jr, Bigler S. A., Bowman G., Kilambi N. K. Race and cause specific survival with prostate cancer: influence of clinical stage, Gleason score, age and treatment. J Urol. 2000 Jan;163(1):137–142. doi: 10.1016/s0022-5347(05)67989-x. [DOI] [PubMed] [Google Scholar]
  6. Glass Tracy R., Tangen Catherine M., Crawford E. David, Thompson Ian. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003 Jan;169(1):164–169. doi: 10.1016/S0022-5347(05)64059-1. [DOI] [PubMed] [Google Scholar]
  7. Greenlee R. T., Murray T., Bolden S., Wingo P. A. Cancer statistics, 2000. CA Cancer J Clin. 2000 Jan-Feb;50(1):7–33. doi: 10.3322/canjclin.50.1.7. [DOI] [PubMed] [Google Scholar]
  8. Hoffman R. M., Gilliland F. D., Eley J. W., Harlan L. C., Stephenson R. A., Stanford J. L., Albertson P. C., Hamilton A. S., Hunt W. C., Potosky A. L. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2001 Mar 7;93(5):388–395. doi: 10.1093/jnci/93.5.388. [DOI] [PubMed] [Google Scholar]
  9. Jemal Ahmedin, Murray Taylor, Samuels Alicia, Ghafoor Asma, Ward Elizabeth, Thun Michael J. Cancer statistics, 2003. CA Cancer J Clin. 2003 Jan-Feb;53(1):5–26. doi: 10.3322/canjclin.53.1.5. [DOI] [PubMed] [Google Scholar]
  10. Logothetis C. J., Samuels M. L., von Eschenbach A. C., Trindade A., Ogden S., Grant C., Johnson D. E. Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol. 1983 Jun;1(6):368–379. doi: 10.1200/JCO.1983.1.6.368. [DOI] [PubMed] [Google Scholar]
  11. Mebane C., Gibbs T., Horm J. Current status of prostate cancer in North American black males. J Natl Med Assoc. 1990 Nov;82(11):782–788. [PMC free article] [PubMed] [Google Scholar]
  12. Morton R. A., Jr Racial differences in adenocarcinoma of the prostate in North American men. Urology. 1994 Nov;44(5):637–645. doi: 10.1016/s0090-4295(94)80196-7. [DOI] [PubMed] [Google Scholar]
  13. Optenberg S. A., Thompson I. M., Friedrichs P., Wojcik B., Stein C. R., Kramer B. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA. 1995 Nov 22;274(20):1599–1605. [PubMed] [Google Scholar]
  14. Pettaway C. A. Racial differences in the androgen/androgen receptor pathway in prostate cancer. J Natl Med Assoc. 1999 Dec;91(12):653–660. [PMC free article] [PubMed] [Google Scholar]
  15. Pettaway C. A., Troncoso P., Ramirez E. I., Johnston D. A., Steelhammer L., Babaian R. J. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol. 1998 Aug;160(2):437–442. [PubMed] [Google Scholar]
  16. Powell I. J., Schwartz K., Hussain M. Removal of the financial barrier to health care: does it impact on prostate cancer at presentation and survival? A comparative study between black and white men in a Veterans Affairs system. Urology. 1995 Dec;46(6):825–830. doi: 10.1016/S0090-4295(99)80352-5. [DOI] [PubMed] [Google Scholar]
  17. Sabbatini P., Larson S. M., Kremer A., Zhang Z. F., Sun M., Yeung H., Imbriaco M., Horak I., Conolly M., Ding C. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999 Mar;17(3):948–957. doi: 10.1200/JCO.1999.17.3.948. [DOI] [PubMed] [Google Scholar]
  18. Sakr W. A., Grignon D. J., Haas G. P., Schomer K. L., Heilbrun L. K., Cassin B. J., Powell J., Montie J. A., Pontes J. E., Crissman J. D. Epidemiology of high grade prostatic intraepithelial neoplasia. Pathol Res Pract. 1995 Sep;191(9):838–841. doi: 10.1016/s0344-0338(11)80965-9. [DOI] [PubMed] [Google Scholar]
  19. Soloway M. S., Hardeman S. W., Hickey D., Raymond J., Todd B., Soloway S., Moinuddin M. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988 Jan 1;61(1):195–202. doi: 10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  20. Soloway M. S., Ishikawa S., van der Zwaag R., Todd B. Prognostic factors in patients with advanced prostate cancer. Urology. 1989 May;33(5 Suppl):53–56. doi: 10.1016/0090-4295(89)90107-6. [DOI] [PubMed] [Google Scholar]
  21. Thompson I., Tangen C., Tolcher A., Crawford E., Eisenberger M., Moinpour C. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst. 2001 Feb 7;93(3):219–225. doi: 10.1093/jnci/93.3.219. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES